Post-Market Surveillance of Tobacco Products

Completed · Not applicable

Conditions studied: Smoking, Tobacco, Smoking Behaviors

In brief

This is a multicenter, post market surveillance study designed to evaluate biomarkers of tobacco exposure and effect, health status measurements, and tobacco product usage patterns in subjects who are natural adopters of cigarettes and/or smokeless tobacco. Non tobacco users will serve as a non use comparison group. This study is unblinded by necessity due to the very different visual appearance of the subject's Usual Brand (UB) of tobacco product(s).

Key facts

Study ID

NCT04255459

Run by

RAI Services Company

People needed

320

Starts

2010-02-13

Expected to finish

2010-08-14

Last updated by the study team

2020-02-05

Who can join

Age: 19 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Able to comprehend and willing to sign an informed consent form.
• Male or female subjects at least 19 years of age.
• Able to safely perform all study procedures, as determined by the site Investigator.
• Willing to perform all study procedures and to consume only the meals/snacks provided while confined to the clinic.
• Agree to not use drugs of abuse over the course of the study, and test negative for drugs of abuse.
• Test negative for breath alcohol (by breathalyzer).
• For tobacco users: do NOT intend to quit smoking nor intend to quit using oral smokeless tobacco products (STP) leading up to study participation (defined as planning a quit attempt within a month of the Initial Screening Visit).
• For tobacco users: willing to abstain from tobacco use for up to 10 hours during overnight confinement in the clinic.
• Able to read, understand, and complete questionnaires in English.
• Meet cohort specific requirements as follows:
• Moist Snuff Users: Must be exclusive moist snuff users of any brand, any style, and any flavor who self-report using on average ≥ 1 can per week for at least 6 months prior to study entry, have an expired carbon monoxide (ECO) level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
• Camel SNUS Users: Must be exclusive Camel SNUS users of any variety who self report using on average ≥ 1 tin per week for at least 6 months prior to study entry, have an ECO level of 0 to 5 ppm, and have a positive urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.
• Dual Camel SNUS/Cigarette Users: Must be dual users of Camel SNUS and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 tin of Camel SNUS per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
• Dual Moist Snuff/Cigarette Users: Must be dual users of moist snuff and allowed commercial filtered tobacco burning cigarettes, using on average ≥ 1 can of snuff per week and smoking ≥ 5 cigarettes daily for at least 6 months prior to study entry. The subject's ECO level must be from 5 to 100 ppm, and the urine cotinine screen must be positive.
• Cigarette Smokers: Must be exclusive cigarette smokers (of allowed commercial filtered tobacco burning cigarettes) who self-report smoking on average ≥ 10 cigarettes daily for at least 6 months prior to study entry, have an ECO level of 10 to 100 ppm, and have a positive urine cotinine screen.
• Non Tobacco Users: Must be non tobacco users for at least 12 months prior to study entry with an ECO level of 0 to 5 ppm, and have a negative urine cotinine screen. Note: Subjects with an ECO level of 6 to 10 ppm may be included upon joint review by the Sponsor and Investigator.

You may not qualify if…

• Use of any type of non-tobacco nicotine-containing product/device (e.g., electronic cigarette) or any nicotine replacement therapy (e.g., nicotine patch, nicotine gum, nicotine spray, nicotine inhaler or nicotine lozenge) within 6 months prior to study entry or during the study.
• Unable to safely perform the study procedures, as determined by the site Investigator. In general, subjects with any of the conditions listed below will be excluded unless individually approved by the Medical Monitor.
• Uncontrolled hypertension (blood pressure > 170/110 mmHg at the Initial Screening Visit).
• Unstable coronary artery disease (Class III-IV angina).
• Decompensated (Class III-IV) congestive heart failure.
• Morbid obesity (body mass index [BMI] ≥ 40 kg/m2).
• Uncontrolled diabetes (HgbA1c > 9.0).
• Pulmonary disease requiring oxygen therapy or preventing 6 minutes of steady ambulation or preventing completion of triplicate spirometry.
• Reduced mobility that impairs satisfactory completion of the 6MWT (six minute walk test), such as:
• i. Clinically significant arthritis of the knee or hip.
• ii. Claudication with walking 6 minutes or less.
• iii. Clinically significant ambulation impairment as sequelae of cerebrovascular accident (CVA), sciatica, peripheral nervous disease, or myopathy.
• iv. Imbalance or other gait disorder requiring assistance of a cane or walker to ambulate.
• Have a resting heart rate (after being seated for at least 5 minutes) of > 120 beats per minute (bpm).
• Had a myocardial infarction within the month prior to the Initial Screening Visit through enrollment into the study.
• Have self reported or clinical indications of psychiatric disorders deemed clinically significant by the site Investigator.
• Unwilling to perform the study procedures.
• For females: intend to get pregnant during study period, or are currently pregnant or breast feeding.
• For cigarette- and dual-users:
• use of any charcoal-filtered cigarette (i.e., brands such as Lark, Kent, etc., with the word "charcoal" on the package),
• use of any crush-capsule cigarette (such as Camel Crush or Pall Mall Crush), or
• use of any non tobacco burning cigarette, including tobacco heating cigarettes (such as Eclipse, Accord, etc.) or electronic cigarettes (e-cigarettes such as Smoking Anywhere, Gamucci, NJOY, etc.).
• For tobacco users: express an interest in quitting smoking or using oral smokeless tobacco (defined as planning a quit attempt within a month of the Initial Screening Visit).
• Have participated in a clinical study and/or received an investigational product within 30 days of the Initial Screening Visit.
• Meet cohort specific exclusions as follows:

Where it is running

• Avail Clinical Research — DeLand, Florida, United States
• Comprehensive Clinical Development, Inc. — Miramar, Florida, United States
• Clinical Research Atlanta — Stockbridge, Georgia, United States
• Central Kentucky Research Associates (CKRA) — Lexington, Kentucky, United States
• MetaClin Research, Inc. — Austin, Texas, United States
• Community Clinical Research — Austin, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.